Clinical Trials
6 trialsNCT07618546 2026-06-01
A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors
Henan Cancer Hospital
Phase NA Not yet recruiting
NCT06893887 2025-07-02
ICT-HCC
Nanjing Tianyinshan Hospital
Phase NA Recruiting
NCT04559607 2023-12-18
TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma
Zhongda Hospital
Phase NA Unknown
NCT03722875 2018-12-19
SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery
Shanghai Zhongshan Hospital
Phase NA Unknown
NCT03398122 2018-01-12
HCC
Tianjin Medical University Cancer Institute and Hospital
Phase NA Unknown
NCT03066557 2017-02-28
Study of the Combination of TACE With Apatinib in Patients With Hepatocellular Carcinoma
Jiangsu Cancer Institute & Hospital
Phase NA Unknown